

PharmaLedger Consortium Endorses Creation of the PharmaLedger Association to Globally Scale the Project's Outcomes

September 25, 2022 –

The PharmaLedger project announces its strategy to sustain the outcomes of its 36-month project. The consortium of 29 public and private members has formally endorsed the sustainability plan of the project's results. The endorsement is a major milestone achievement for the project.

The endorsement represents the realisation of the project's main objective of delivering a widely trusted blockchain-based platform and underpins the creation of the **PharmaLedger Association (PLA)**; a not-for-profit organisation that will make possible the deployment of the digital products developed during the project as well as incubation of new blockchain-based healthcare solutions that brings value to patients and to healthcare.

PharmaLedger will now fully implement the approved sustainability plan and will actively recruit members to continue the journey beyond the project's end. The PharmaLedger Association initial funding rounds will take place from October through January.

Key components of PharmaLedger's post-project governance approach:

- **“PharmaLedger Association”** - The project established a not-for-profit association based in Basel, Switzerland with the purpose *“to enable and foster a Digital Trust Ecosystem (DTE) in healthcare through a standardised and trusted open-source platform. The Association promotes collaboration and accelerates innovation and adoption to achieve mutual benefits in the healthcare and life science domains for patients and other stakeholders.”*
- The newly created PharmaLedger Association is being added to the consortium, as its 30th member, thereby granting it access to the project's outcomes and the use of project resources for formation activities.
- The consortium endorsed the proposed bylaws of the Association including core values, membership classes and fees, composition of the Board of Directors and continuous investment in innovation activities. The Association is designed to ensure:
 - Product qualification, leadership, and launch
 - Quality and privacy compliance
 - Technical design, operation, and oversight
 - Continuous innovation investments and incubation for projects
 - Marketing and membership management
 - Secretariat and administration
 - Patient and diverse ecosystem representation at Board level



“The multi-stakeholder consortium partners of the IMI project PharmaLedger have enabled a unique opportunity to make several pharmaceutical processes of direct relevance for patients and their physicians much safer and trustworthy. EFGCP has strongly supported the creation of the PharmaLedger Association to ensure that patients, physicians and other involved stakeholders can increasingly benefit from the innovation provided by this IMI project in future” Ingrid Klingmann, Chairman European Forum for Good Clinical Practice (EFGCP)

“The endorsement of the future governance and operational design is the culmination of years of hard work and passionate leadership by the consortium members. It is proof that we can and will deliver on the promise of blockchain enabled healthcare in the future. I feel very fortunate to be a part of this journey and can't wait to make it a reality with productive solutions that bring value to patients!”

Daniel Fritz, PharmaLedger Industry Project Leader, Novartis

“Collaborative innovation is leading PharmaLedger to higher chances of achieving greater impact to society and in healthcare. We are moving to become a real-world Healthcare Digital Trust Ecosystem. Opening-up to new external partners is exciting! I hope that people and organisations will join the PharmaLedger Association on this journey to collaborate under common values and future opportunities that will improve other lives.” Xenia Beltran, LiFesTech, Universidad Politécnica de Madrid

“The PLA endorsement further solidifies PharmaLedger's initiatives as a sustainable solution for the responsible digitalisation of our global healthcare system. We look forward to the collaboration opportunities the PLA will create as we continue to work together as one team, focused on improving patient access to vital, lifesaving information.” Michael Ritter, Head Serialisation & Digital Enabling, Takeda.

Outlook - As part of the “Validation and Sustainability” focus for the remainder of 2022, the project will:

- Implement and transition to the post-project governance and operating model
- Actively engage with industry and other stakeholders, inviting them to join the Digital Trust Ecosystem journey
- Document, disseminate and publish its results including broad promotion and engagement with 3rd parties
- Run funding rounds aimed at supporting the first 3 years of the Association
- Finalise the qualification of its first digital product – ‘*Electronic Product Information*’ in preparation for an early 2023 launch.

Contact – any inquiries concerning information or membership can be sent to: contact@pharmaledger.org

About PharmaLedger

Sponsored by the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) under the Horizon 2020 programme, PharmaLedger is a 36-month project that brings together 12 global pharmaceutical companies and 18 public and private entities: including technical, legal, regulatory, academia, research, and patient representative organisations. The goal of the project is to provide a widely trusted platform that supports the design and adoption of blockchain-enabled healthcare solutions while accelerating delivery of innovation that benefits the entire ecosystem, from manufacturers to patients.

Consortium Members:

- Universidad Politécnica de Madrid (Project Coordinator) - ES
- Novartis (Industry Leader) – CH
- Projecto Desenvolvimento Manutenção Formação e Consultadoria, Lda - PT
- RomSoft SRL - RO
- Arteevo Technologies Ltd. - IL
- Technovative Solutions Ltd. - UK
- EKON Modeling Software Systems Ltd. IL
- Centre for Research and Technology Hellas - GR
- AbbVie INC. - NL
- AstraZeneca AB - SE
- Bayer Aktiengesellschaft - DE
- Boehringer-Ingelheim GmbH - DE
- GlaxoSmithKline Research and Development Limited - UK
- Janssen Pharmaceutica NV - BE
- Merck Sharp & Dohme Corp - US
- Novo Nordisk A/S - DK
- Pfizer Ltd - UK
- F.Hoffmann-La Roche AG - CH
- UCB Biopharma SPRL - BE
- Katholieke Universiteit Leuven - BE
- Onorach Ltd - UK
- National Research and Development Institute for Cryogenics and Isotopic Technologies - RO
- University Hospital Würzburg - DE
- Democritus University of Thrace - GR
- Hospital do Espírito Santo de Évora - PT
- Ospedale Pediatrico Bambino Gesù - IT
- Imprensa Nacional Casa da Moeda - PT
- European Patients Forum - BE
- European Forum for Good Clinical Practice – BE
- **PharmaLedger Association - CH**



<https://www.ih.europa.eu/>

Disclaimer: this communication reflects the author's view and neither IHI nor the European Union or EFPIA are responsible for any use that may be made of the information contained therein. Mention of third parties and products does not constitute an endorsement by any of the consortium members.